TY - JOUR
T1 - The effects of ranibizumab (Lucentis) on retinal function in isolated perfused vertebrate retina
AU - Lüke, M.
AU - Januschowski, K.
AU - Lüke, J.
AU - Peters, S.
AU - Wirtz, N.
AU - Yörük, E.
AU - Lüke, C.
AU - Bartz-Schmidt, K. U.
AU - Grisanti, S.
AU - Szurman, P.
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009/10
Y1 - 2009/10
N2 - Background: Intraocular ranibizumab (Lucentis, Novartis, Basel Switzerland) is the primary choice in the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is known to be a survival factor for neuronal cells. Therefore, blockage of all VEGF isoforms by ranibizumab could induce retinal dysfunction. Methods: Using isolated bovine retinas, the electroretinogram (ERG) was recorded as a transretinal potential using Ag/AgCl electrodes, while the retinas were perfused with an oxygen preincubated nutrient solution. For 45 min, ranibizumab was applied at a concentration of 0.2 mg/ml and alternatively the solvent carrier without the active agent. The ERG was monitored before, during and after exposure. Results: The concentration of 0.2 mg/ml ranibizumab induced a non-significant b-wave reduction of 22.32% after exposure (p=0.13). For the a-wave amplitude only a reduction of 4% was detected (p=0.18). The solvent carrier induced no significant reduction of the a- and bwave amplitudes (p=0.30 and p=0.979, respectively). Conclusion: In the ex vivo model, the isolated perfused vertebrate retina, ranibizumab has been proven to be a safe compound at the concentrations applied. The stability of the ERG-amplitudes rules out a considerable retinal dysfunction after an injection of up to 1 mg ranibizumab.
AB - Background: Intraocular ranibizumab (Lucentis, Novartis, Basel Switzerland) is the primary choice in the treatment of neovascular age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is known to be a survival factor for neuronal cells. Therefore, blockage of all VEGF isoforms by ranibizumab could induce retinal dysfunction. Methods: Using isolated bovine retinas, the electroretinogram (ERG) was recorded as a transretinal potential using Ag/AgCl electrodes, while the retinas were perfused with an oxygen preincubated nutrient solution. For 45 min, ranibizumab was applied at a concentration of 0.2 mg/ml and alternatively the solvent carrier without the active agent. The ERG was monitored before, during and after exposure. Results: The concentration of 0.2 mg/ml ranibizumab induced a non-significant b-wave reduction of 22.32% after exposure (p=0.13). For the a-wave amplitude only a reduction of 4% was detected (p=0.18). The solvent carrier induced no significant reduction of the a- and bwave amplitudes (p=0.30 and p=0.979, respectively). Conclusion: In the ex vivo model, the isolated perfused vertebrate retina, ranibizumab has been proven to be a safe compound at the concentrations applied. The stability of the ERG-amplitudes rules out a considerable retinal dysfunction after an injection of up to 1 mg ranibizumab.
UR - http://www.scopus.com/inward/record.url?scp=70349972616&partnerID=8YFLogxK
U2 - 10.1136/bjo.2009.157511
DO - 10.1136/bjo.2009.157511
M3 - Journal articles
C2 - 19628500
AN - SCOPUS:70349972616
SN - 0007-1161
VL - 93
SP - 1396
EP - 1400
JO - British Journal of Ophthalmology
JF - British Journal of Ophthalmology
IS - 10
ER -